Astellas Pharma Inc. (4503.T)
JPY 1521.5
(0.8%)
JPY 1521.5
(0.8%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 670.02 Billion JPY | 478.9% |
| 2022 | -176.83 Billion JPY | -71.28% |
| 2021 | -103.24 Billion JPY | -115.7% |
| 2020 | -47.86 Billion JPY | -150.41% |
| 2019 | 94.94 Billion JPY | 130.64% |
| 2018 | -309.87 Billion JPY | 6.21% |
| 2017 | -330.38 Billion JPY | 2.62% |
| 2016 | -339.28 Billion JPY | 5.44% |
| 2015 | -358.8 Billion JPY | 9.33% |
| 2014 | -395.71 Billion JPY | -1.32% |
| 2013 | -390.56 Billion JPY | -67.57% |
| 2012 | -233.07 Billion JPY | -10.47% |
| 2011 | -210.98 Billion JPY | -47.65% |
| 2010 | -142.89 Billion JPY | 54.23% |
| 2009 | -312.19 Billion JPY | -16.73% |
| 2008 | -267.46 Billion JPY | 41.92% |
| 2007 | -460.48 Billion JPY | -9.42% |
| 2006 | -420.84 Billion JPY | 10.92% |
| 2005 | -472.44 Billion JPY | -12.9% |
| 2004 | -418.45 Billion JPY | -24.01% |
| 2003 | -337.43 Billion JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 689.72 Billion JPY | 2.94% |
| 2024 Q2 | 634.5 Billion JPY | -8.01% |
| 2023 Q4 | 670.02 Billion JPY | 8.59% |
| 2023 FY | 670.02 Billion JPY | 478.9% |
| 2023 Q3 | 617 Billion JPY | 11.05% |
| 2023 Q2 | 555.61 Billion JPY | 374.4% |
| 2023 Q1 | -202.48 Billion JPY | -14.51% |
| 2022 FY | -176.83 Billion JPY | -71.28% |
| 2022 Q2 | -278.68 Billion JPY | -38.38% |
| 2022 Q3 | -233.07 Billion JPY | 16.36% |
| 2022 Q4 | -176.83 Billion JPY | 24.13% |
| 2022 Q1 | -201.39 Billion JPY | -95.07% |
| 2021 FY | -103.24 Billion JPY | -115.7% |
| 2021 Q1 | -100.55 Billion JPY | -110.09% |
| 2021 Q2 | -113.45 Billion JPY | -12.83% |
| 2021 Q3 | -148.67 Billion JPY | -31.04% |
| 2021 Q4 | -103.24 Billion JPY | 30.56% |
| 2020 FY | -47.86 Billion JPY | -150.41% |
| 2020 Q1 | -237.11 Billion JPY | -396.47% |
| 2020 Q4 | -47.86 Billion JPY | 84.32% |
| 2020 Q2 | -283.98 Billion JPY | -19.77% |
| 2020 Q3 | -305.26 Billion JPY | -7.49% |
| 2019 Q3 | -274.44 Billion JPY | 11.01% |
| 2019 FY | 94.94 Billion JPY | 130.64% |
| 2019 Q2 | -308.4 Billion JPY | -19.62% |
| 2019 Q1 | -257.82 Billion JPY | 16.49% |
| 2019 Q4 | 79.97 Billion JPY | 129.14% |
| 2018 Q1 | -306.23 Billion JPY | 6.44% |
| 2018 Q4 | -308.73 Billion JPY | 6.37% |
| 2018 Q3 | -329.72 Billion JPY | -8.82% |
| 2018 FY | -309.87 Billion JPY | 6.21% |
| 2018 Q2 | -302.99 Billion JPY | 1.06% |
| 2017 FY | -330.38 Billion JPY | 2.62% |
| 2017 Q1 | -310.64 Billion JPY | 8.46% |
| 2017 Q4 | -327.31 Billion JPY | 0.19% |
| 2017 Q3 | -327.92 Billion JPY | -7.81% |
| 2017 Q2 | -304.16 Billion JPY | 2.09% |
| 2016 Q2 | -365.45 Billion JPY | -17.58% |
| 2016 FY | -339.28 Billion JPY | 5.44% |
| 2016 Q4 | -339.34 Billion JPY | 2.44% |
| 2016 Q3 | -347.81 Billion JPY | 4.83% |
| 2016 Q1 | -310.82 Billion JPY | 13.11% |
| 2015 FY | -358.8 Billion JPY | 9.33% |
| 2015 Q2 | -386.38 Billion JPY | -4.26% |
| 2015 Q1 | -370.61 Billion JPY | 6.34% |
| 2015 Q3 | -338.74 Billion JPY | 12.33% |
| 2015 Q4 | -357.7 Billion JPY | -5.6% |
| 2014 Q2 | -421.27 Billion JPY | -12.96% |
| 2014 Q4 | -395.71 Billion JPY | 9.64% |
| 2014 Q3 | -437.91 Billion JPY | -3.95% |
| 2014 FY | -395.71 Billion JPY | -1.32% |
| 2014 Q1 | -372.94 Billion JPY | 4.51% |
| 2013 Q2 | -258.65 Billion JPY | -10.27% |
| 2013 Q3 | -303.43 Billion JPY | -17.31% |
| 2013 Q4 | -390.56 Billion JPY | -28.71% |
| 2013 FY | -390.56 Billion JPY | -67.57% |
| 2013 Q1 | -234.56 Billion JPY | -0.64% |
| 2012 Q4 | -233.07 Billion JPY | 4.07% |
| 2012 Q3 | -242.96 Billion JPY | -26.86% |
| 2012 Q2 | -191.52 Billion JPY | -0.98% |
| 2012 Q1 | -189.66 Billion JPY | 10.11% |
| 2012 FY | -233.07 Billion JPY | -10.47% |
| 2011 FY | -210.98 Billion JPY | -47.65% |
| 2011 Q2 | -206.35 Billion JPY | -24.3% |
| 2011 Q1 | -166.01 Billion JPY | -16.18% |
| 2011 Q4 | -210.98 Billion JPY | 2.52% |
| 2011 Q3 | -216.44 Billion JPY | -4.89% |
| 2010 Q4 | -142.89 Billion JPY | -1.67% |
| 2010 FY | -142.89 Billion JPY | 54.23% |
| 2010 Q3 | -140.54 Billion JPY | 8.82% |
| 2010 Q1 | -131.64 Billion JPY | 57.83% |
| 2010 Q2 | -154.14 Billion JPY | -17.09% |
| 2009 FY | -312.19 Billion JPY | -16.73% |
| 2009 Q2 | -276.57 Billion JPY | 0.0% |
| 2009 Q4 | -312.19 Billion JPY | -11.83% |
| 2009 Q3 | -279.16 Billion JPY | -0.94% |
| 2008 Q4 | -267.46 Billion JPY | 0.0% |
| 2008 FY | -267.46 Billion JPY | 41.92% |
| 2007 FY | -460.48 Billion JPY | -9.42% |
| 2006 FY | -420.84 Billion JPY | 10.92% |
| 2005 FY | -472.44 Billion JPY | -12.9% |
| 2004 FY | -418.45 Billion JPY | -24.01% |
| 2003 FY | -337.43 Billion JPY | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Kyowa Kirin Co., Ltd. | -378.83 Billion JPY | 276.865% |
| Chugai Pharmaceutical Co., Ltd. | -445.21 Billion JPY | 250.494% |
| Ono Pharmaceutical Co., Ltd. | -157.27 Billion JPY | 526.013% |
| Santen Pharmaceutical Co., Ltd. | -59.42 Billion JPY | 1227.539% |
| JCR Pharmaceuticals Co., Ltd. | 4.54 Billion JPY | -14645.357% |
| Daiichi Sankyo Company, Limited | -259.26 Billion JPY | 358.437% |
| Otsuka Holdings Co., Ltd. | -299.15 Billion JPY | 323.975% |
| Perseus Proteomics Inc. | -1.54 Billion JPY | 43568.324% |